Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

AMENDMENT NO. 1 TO
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 2, 2007

Brainstorm Cell Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware
 
 
333-61610
 
 
20-8133057
(State or other jurisdiction of incorporation)
 
 
(Commission File No.)
 
 
(IRS Employer Identification No.)
 
110 East 59 th Street
 
New York, New York
10022
(Address of principal executive offices)
(Zip Code)

(212) 557-9000
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Explanatory Note

On July 5, 2007, Brainstorm Cell Therapeutics Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report) to report the appointment of Mr. Chaim Lebovits as the Company’s President. The Company explained in the Original Report that the Company had not determined the compensation of Mr. Lebovits as of the date of filing the Original Report. The Company is filing this amendment to the Original Report to report the compensation of Mr. Lebovits.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On February 11, 2008, Brainstorm Cell Therapeutics Inc. and Brainstorm Cell Therapeutics Ltd. (collectively, “Brainstorm”) and Chaim Lebovits, the Company’s President, agreed that Brainstorm would provide Mr. Lebovits with a salary of 37,450 NIS (New Israeli Shekels) (approximately $10,400) per month starting February 15, 2008. Brainstorm and Mr. Lebovits have not yet entered into a written agreement.
 


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
February 21, 2008
Brainstorm Cell Therapeutics Inc.
 
 		  
 		  
 
  By:   /s/ Rami Efrati
 
Rami Efrati
 
Chief Executive Officer